Raykov Rosty's Form 4 filing
Fennec Pharmaceuticals Inc. (FENC) · filed Jan 5, 2026
- Accession no.
- 0001468316-26-000002
- Filed
- Jan 5, 2026
- Trade date
- Dec 31, 2025-Jan 2, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $78.4K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Raykov RostyCIK 0001468316 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | Common shares | AGrant or awardAcquired | +5,208 | $0.00 | $0 | 82,734 | Direct | |
| Jan 2, 2026 | Common shares | MOption exerciseAcquired | +15,598 | $2.45 | +$38,215.1 | 98,332 | Direct | |
| Jan 2, 2026 | Common shares | SSaleDisposed | −10,312 | $7.60 | −$78,371.2 | 88,020 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Options | MOption exerciseDisposed | −15,598 | $2.45 | −$38,215.1 | 1,618,586 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.